FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Roche news from FierceBiotech

News

Novartis extends $700M Alnylam pact

Novartis has extended its pact with Alnylam through October 2009. The deal, which is worth up to $700 million Read more...
Tags: Roche   RNAi   Alnylam  

In fresh blow, Roche shutters HIV research program

In another big blow to the AIDS research field, pharma giant Roche is dumping its R&D work in the field. The Financial Times reports that disappointing clinical results had persuaded Roche to Read more...
Tags: HIV/AIDS   Roche  

Sangamo, Sigma-Aldrich ink Roche deal

Sangamo and Sigma-Aldrich have inked a deal with Roche for the use of zinc finger nuclease (ZFN) technology to develop cell-lines and transgenic animals that have targeted modifications in a Read more...

Roche CEO: Emphasizing drugs for primary care

The new CEO at Roche is sending out some strong signals that the pharma giant's development process will include more new therapies for primary care. Roche is a big player in the field of Read more...
Tags: Avastin   Severin Schwan   Roche  

Roche oncology chief sees big impact of sugar tech

Three years after plunking down $180 million to buy GlycArt, Roche says the sugar-related technology it acquired in the deal is demonstrating striking effectiveness enhancing experimental cancer Read more...
Tags: GlycArt   Roche   David Heimbrook  

Roche signs up for $774M development pact

Roche has forged a $774 million deal to license an early stage cancer drug from Belgium's ThromboGenics and Sweden's BioInvent. In the deal, ThromboGenics gets a whopping $77.4 million upfront Read more...
Tags: ThromboGenics   TB-403   Roche   BioInvent  

Inimex raises $22M in VC

Despite a recent Ernst & Young report on the funding challenges in Canada, Inimex Read more...

SPOTLIGHT: Pertuzumab slows breast cancer in study

Roche announced that a combination of Herceptin and pertuzumab slowed the spread of breast Read more...
Tags: breast cancer   Herceptin   Roche  

Roche posts new data backing Actemra for RA

Roche has racked up more late-stage data backing Actemra as a new therapy for rheumatoid arthritis. Researchers say their fifth Phase III trial demonstrated that the therapy inhibited structural Read more...

Roche expands Memory pact

Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' drug candidate, MEM 3454, for various neurological and psychiatric disorders. Memory gets a $6 million Read more...

Press Releases

PRESS RELEASE: Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic

Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic Summary: An IND has Been Filed With the FDA for the Fourth Genmab Antibody Developed Under the Company's Collaboration with Read more...

PRESS RELEASE: FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing

FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy Read more...

PRESS RELEASE: Roche Confirms Commencement of Due Diligence with Ventana

Roche Confirms Commencement of Due Diligence with Ventana Roche confirmed today that it has entered into a confidentiality agreement with Ventana Medical Systems, Inc. (NASDAQ: VMSI) and that it Read more...

PRESS RELEASE: Ventana Enters into Confidentiality Agreement with Roche

Ventana Enters into Confidentiality Agreement with Roche TUCSON, Ariz. -- Nov. 13, 2007--Ventana Medical Systems, the global leader in tissue-based cancer diagnostics, today announced it has entered Read more...

PRESS RELEASE: Roche signs licensing and settlement agreements for Hepatitis C immunodiagnostics

Roche signs licensing and settlement agreements for Hepatitis C immunodiagnostics Roche announced today licensing and settlement agreements with Ortho-Clinical Diagnostics, Inc. and Novartis Read more...

Get more Roche coverage at: